These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 20107793)
1. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680 [TBL] [Abstract][Full Text] [Related]
5. The added value of Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022 [TBL] [Abstract][Full Text] [Related]
6. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers. Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538 [TBL] [Abstract][Full Text] [Related]
7. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518 [TBL] [Abstract][Full Text] [Related]
8. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Ambrosini V; Campana D; Nanni C; Cambioli S; Tomassetti P; Rubello D; Fanti S Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1278-83. PubMed ID: 22584487 [TBL] [Abstract][Full Text] [Related]
9. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242 [TBL] [Abstract][Full Text] [Related]
10. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of ⁶⁸Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Naswa N; Sharma P; Nazar AH; Agarwal KK; Kumar R; Ammini AC; Malhotra A; Bal C Eur Radiol; 2012 Mar; 22(3):710-9. PubMed ID: 21971823 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of [ Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796 [TBL] [Abstract][Full Text] [Related]
13. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183 [TBL] [Abstract][Full Text] [Related]
14. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343 [TBL] [Abstract][Full Text] [Related]